Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

Slides:



Advertisements
Similar presentations
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Advertisements

Cardiovascular Challenges in Diabetes
Cardiovascular Outcomes Trials in Diabetes: The Truth, the Whole Truth, and Nothing But the Truth.
Diabetic Dyslipidemia in Practice
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?
New Data on the Safety of SGLT2 Inhibitors
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
Updates on CVOT Data and Clinical Comparisons That Matter
Global Projections for Diabetes:
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
SGLT2 Inhibitors in Phase 3 Trials
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Updates Abound.
SGLT2 Inhibitors in the Modern Era: Why and Where?
Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
SGLT2 Inhibitors and CV Outcomes
Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.
Clinical Application of New CV Outcomes Data
GLP-1 Receptor Agonists: How Early Is Appropriate?
The Evolving Role of Immunotherapy in NSCLC
A Deep Dive Into CVOTs.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.
SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Next-Gen Psoriasis Therapies:
Case Study Role of DPP-4 Inhibitors
Tackling CV Risk in T2DM.
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Early and Intensive T2D Management:
Breaking Down the CVOTs
EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Novel Approaches in T1D Management
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?
Type 2 Diabetes Management:  Where Are We Heading in Our Efforts to Control CV Risk?
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?
Antihyperglycemic Therapy
CV Outcomes and Adherence With GLP-1 RAs
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
The Role of the Kidney in Glucose Control
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Add-On Therapy to Insulin in T1DM Management
Patient Selection for Modern T2D Agents
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
Improving Overall Health
2015 EASD In Review: CV Risk management in t2dm
ADA/EASD general recommendations for type 2 diabetes management (1).
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Glucose-lowering medication in type 2 diabetes: overall approach.
What's New in Oral Combination Therapy for Type 2 Diabetes?
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Top Tips in Evidence-Based Care for HFrEF
Expert Perspectives.
Antihyperglycemic therapy in adults with type 2 diabetes
The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum
The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?
Presentation transcript:

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents

Management Guidelines for Hyperglycemia in Type 2 Diabetes

Management Guidelines for Hyperglycemia in Type 2 Diabetes (cont)

Case Study #1: Marcus

Case Discussion: Role of DPP-4 Inhibitors

DPP-4 Inhibitor Safety Concerns

Case Study #2: Joseph

Case Discussion: Role of SGLT2 Inhibitors

Other Warnings for SGLT2 Inhibitors

Cardiovascular Benefit With SGLT2 Inhibitors

Case Study #3: Emily

Case Discussion: Role of GLP-1 Agonists

GLP-1 Agonists Promote Weight Loss

LEADER: Cardiovascular Outcomes Trial With Liraglutide

Warnings for GLP-1 Agonists

Closing Remarks

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.